Merck Raises Low End of Year EPS View by 2c; 2Q Adj. EPS Beat
Source: BFW (Bloomberg First Word)
Tickers
MRK US (Merck & Co Inc)
CSL AU (CSL Ltd)
JNJ US (Johnson & Johnson)
4508 JP (Mitsubishi Tanabe Pharma Corp)
People
Kenneth Frazier (Merck & Co Inc)
To de-activate this alert, click here
UUID: 7947283
(Bloomberg) -- Merck raises year adj. EPS view to $3.67-$3.77, had seen $3.65-$3.77 in May, est. $3.72 (range $3.66-$3.77); forecast includes 1% negative FX effect.
Alert: HALISTER- Narrows year rev. view to $39.1b-$40.1b vs $39.0b-$40.2b prior, est. $39.5b, includes negative 2% FX effect
- 2Q adj. EPS 93c, est. 91c (range 84c-94c).
- 2Q rev. $9.84b, est. $9.79b
- Product sales:
- Januvia+Janumet $1.634b, est. $1.598b
- Zetia + Vytorin $994m vs $955m y/y
- Gardasil/Gardasil 9 $393m, may not compare to est. $457.2m
- Proquad/MMR II/Varivax $383m vs $358m y/y
- Cubicin $357m, est. $282.1m
- Remicade $339m, est. $325.1m
- Isentress $338m, est. $347.4m
- Keytruda $314m, est. $287.2m
- Animal Health rev. $898m vs $840m y/y
- “Business development remains a critical component” of strategy; is “actively engaged in seeking external opportunities to complement and strengthen” pipeline and portfolio: CEO Kenneth C. Frazier
- MRK EARNINGS PREVIEW: Keytruda Performance; Impacts of SGLT2s
- Call 8am 706-758-9927 pw 34462082
Source: BFW (Bloomberg First Word)
Tickers
MRK US (Merck & Co Inc)
CSL AU (CSL Ltd)
JNJ US (Johnson & Johnson)
4508 JP (Mitsubishi Tanabe Pharma Corp)
People
Kenneth Frazier (Merck & Co Inc)
To de-activate this alert, click here
UUID: 7947283